Article Details
Retrieved on: 2024-01-22 17:23:59
Tags for this article:
Click the tags to see associated articles and topics
Summary
Gilead Sciences' antibody-drug conjugate Trodelvy did not achieve a statistically significant improvement in lung cancer survival compared to chemotherapy, potentially affecting its competition with similar drugs and Gilead's oncology market presence.
Article found on: www.biopharmadive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here